First Time Loading...

Amgen Inc
NASDAQ:AMGN

Watchlist Manager
Amgen Inc Logo
Amgen Inc
NASDAQ:AMGN
Watchlist
Price: 279 USD 0.59%
Updated: May 2, 2024
Section:
 

Wall Street
Price Targets

AMGN Price Targets Summary
Amgen Inc

Wall Street analysts forecast AMGN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AMGN is 313.65 USD with a low forecast of 171.7 USD and a high forecast of 399 USD.

AMGN Lowest Forecast
Wall Street Target
171.7 USD
38% Downside
AMGN Average Forecast
Wall Street Target
313.65 USD
12% Upside
AMGN Highest Forecast
Wall Street Target
399 USD
43% Upside
Lowest
Price Target
171.7 USD
38% Downside
Average
Price Target
313.65 USD
12% Upside
Highest
Price Target
399 USD
43% Upside

AMGN Last Price Targets
Amgen Inc

The latest public price target was made on Apr 17, 2024 by Mohit Bansal from Wells Fargo , who expects AMGN stock to rise by 15% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Mohit Bansal
Wells Fargo
320 USD
Upside 15%
2 weeks ago
Apr 17, 2024
Wells Fargo Reiterates Overweight Rating on Amgen (AMGN)
StreetInsider
Jay Olson
Oppenheimer
280 USD
Upside 0%
7 months ago
Sep 13, 2023
These 3 Health Care Stocks With Over 3% Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts
Benzinga
Michael Yee
Jefferies
310 USD
Upside 11%
7 months ago
Sep 13, 2023
These 3 Health Care Stocks With Over 3% Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts
Benzinga
Mohit Bansal
Wells Fargo
265 USD
Downside 5%
1 year ago
Apr 12, 2023
These 3 Health Care Stocks Delivering High-Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts
Benzinga
Mohit Bansal
Wells Fargo
275 USD
Downside 1%
1 year ago
Mar 10, 2023
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks Delivering High-Dividend Yields
Benzinga
Unknown Analyst
Leerink Partners
267 USD
Downside 4%
1 year ago
Feb 2, 2023
SVB Leerink Maintains Market Perform on Amgen, Lowers Price Target to $267
Benzinga
Unknown Analyst
RBC Capital
258 USD
Downside 8%
1 year ago
Feb 1, 2023
RBC Capital Maintains Sector Perform on Amgen, Lowers Price Target to $258
Benzinga
Unknown Analyst
BMO Capital
253 USD
Downside 9%
1 year ago
Feb 1, 2023
BMO Capital Maintains Market Perform on Amgen, Lowers Price Target to $253
Benzinga
Unknown Analyst
Oppenheimer
294 USD
Upside 5%
1 year ago
Feb 1, 2023
Oppenheimer Maintains Outperform on Amgen, Lowers Price Target to $294
Benzinga
Unknown Analyst
Cowen & Co.
289 USD
Upside 4%
1 year ago
Feb 1, 2023
Cowen & Co. Maintains Outperform on Amgen, Lowers Price Target to $289
Benzinga
Show More Price Targets
Show Less Price Targets
Mohit Bansal
Wells Fargo
Price Target 320 USD
Upside/Downside 15%
View Source
Jay Olson
Oppenheimer
Price Target 280 USD
Upside/Downside 0%
View Source
Michael Yee
Jefferies
Price Target 310 USD
Upside/Downside 11%
View Source
Mohit Bansal
Wells Fargo
Price Target 265 USD
Upside/Downside 5%
View Source
Mohit Bansal
Wells Fargo
Price Target 275 USD
Upside/Downside 1%
View Source
Unknown Analyst
Leerink Partners
Price Target 267 USD
Upside/Downside 4%
View Source
Unknown Analyst
RBC Capital
Price Target 258 USD
Upside/Downside 8%
View Source
Unknown Analyst
BMO Capital
Price Target 253 USD
Upside/Downside 9%
View Source
Unknown Analyst
Oppenheimer
Price Target 294 USD
Upside/Downside 5%
View Source
Unknown Analyst
Cowen & Co.
Price Target 289 USD
Upside/Downside 4%
View Source
Show More Price Targets
Show Less Price Targets
Amgen Inc Competitors:
Price Targets
OCC
Orthocell Ltd
46% Upside
1167
Jacobio Pharmaceuticals Group Co Ltd
227% Upside
HALO
Halozyme Therapeutics Inc
33% Upside
ARMP
Armata Pharmaceuticals Inc
240% Upside
OCC
Orthocell Ltd
46% Upside
1167
Jacobio Pharmaceuticals Group Co Ltd
227% Upside
HALO
Halozyme Therapeutics Inc
33% Upside
ARMP
Armata Pharmaceuticals Inc
240% Upside
XNCR
Xencor Inc
56% Upside
TGTX
TG Therapeutics Inc
95% Upside
BIO
Biotest AG
19% Downside
M
MGX
Metagenomi Inc
226% Upside

Revenue
Forecast

Revenue Estimate
Amgen Inc

For the last 8 years the compound annual growth rate for Amgen Inc's revenue is 3%. The projected CAGR for the next 3 years is 8%.

3%
Past Growth
8%
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Amgen Inc

For the last 8 years the compound annual growth rate for Amgen Inc's operating income is -1%. The projected CAGR for the next 3 years is 26%.

-1%
Past Growth
26%
Estimated Growth
Estimates Accuracy
-15%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Amgen Inc

For the last 8 years the compound annual growth rate for Amgen Inc's net income is 0%. The projected CAGR for the next 3 years is 22%.

0%
Past Growth
22%
Estimated Growth
Estimates Accuracy
-18%
Average Miss
What are analyst estimates?

See Also

Summary
AMGN intrinsic value, competitors valuation, and company profile.
DCF Valuation
AMGN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AMGN stock valuation using valuation multiples.
Wall Street Estimates
AMGN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AMGN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is AMGN's stock price target?
Price Target
313.65 USD

According to Wall Street analysts, the average 1-year price target for AMGN is 313.65 USD with a low forecast of 171.7 USD and a high forecast of 399 USD.

What is Amgen Inc's Revenue forecast?
Projected CAGR
8%

For the last 8 years the compound annual growth rate for Amgen Inc's revenue is 3%. The projected CAGR for the next 3 years is 8%.

What is Amgen Inc's Operating Income forecast?
Projected CAGR
26%

For the last 8 years the compound annual growth rate for Amgen Inc's operating income is -1%. The projected CAGR for the next 3 years is 26%.

What is Amgen Inc's Net Income forecast?
Projected CAGR
22%

For the last 8 years the compound annual growth rate for Amgen Inc's net income is 0%. The projected CAGR for the next 3 years is 22%.

ALPHA SPREAD
Join more than 133,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.